Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393055 | 1.00 | CALCA (1.00) | CALCAKMT2ACYP2C9SMN1; SMN2KCNH2 | |
| SCHEMBL4060940 | 0.97 | CALCA (0.95) | CALCAKMT2ACYP2C9SMN1; SMN2KCNH2 | |
| SCHEMBL6046599 | 0.92 | CALCA (1.00) | CALCA | |
| SCHEMBL4063925 | 0.91 | CALCA (0.84) | CALCAKMT2ACYP2C9 | |
| SCHEMBL4058757 | 0.90 | CALCA (0.82) | CALCAKMT2ASMN1; SMN2 | |
| SCHEMBL4060225 | 0.90 | CALCA (0.81) | CALCAKMT2ASMN1; SMN2 | |
| SCHEMBL4067919 | 0.89 | CALCA (0.80) | CALCAKMT2ASMN1; SMN2 | |
| SCHEMBL4060939 | 0.89 | CALCA (0.79) | CALCAKMT2ASMN1; SMN2 | |
| SCHEMBL7263607 | 0.88 | CALCA (0.79) | CALCA | |
| SCHEMBL14260007 | 0.88 | CALCA (0.78) | CALCAKMT2ACYP2C9SMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | claimed |
| US-8211879-B2 | Cationic steroid antimicrobial compositions and methods of use | BRIGHAM YOUNG UNIVERSITY (US) | 2012-07-03 | — | — | US | claimed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | ANTHONY NEVILLE J (US) | 2005-08-11 | — | — | US | claimed |
| US-20050165000-A1 | Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant | ROBERTSON SANDRA K (US) | 2005-07-28 | — | — | US | claimed |
| US-6921759-B2 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-26 | — | — | US | claimed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | claimed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-4005560-B1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3730503-B1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX INC (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4065116-B1 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | GILEAD SCIENCES INC (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2003016309-A1 | PROCESS FOR PREPARING 5-SULFONAMIDO-8-HYDROXY-1, 6-NAPHTHYRIDINE-7-CARBOXAMIDES | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016315-A1 | SODIUM SALT OF AN HIV INTEGRASE INHIBITOR | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | CALCA 4329/4885KMT2A 1290/4885CYP2C9 2789/4885 |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | CALCA 3366/4885KMT2A 61/4885CYP2C9 2675/4885 |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | CALCA 3366/4885KMT2A 61/4885CYP2C9 2675/4885 |
| US-20050165000-A1 | Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant | CDK7, INTS6, POLA1 | CALCA 4164/4885KMT2A 1208/4885CYP2C9 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.